Literature DB >> 2076932

Intravesical bacillus Calmette-Guérin administration in the prophylaxis of superficial bladder cancer.

M D Melekos1, A Pantazakos, S Markou, C Skopa, A Athanassopoulos, G Barbalias.   

Abstract

A total of 68 patients received prophylactic/adjuvant intravesical Pasteur strain bacillus Calmette-Guérin (BCG) instillations following transurethral resection for superficial bladder carcinoma. An induction phase consisting of 6 weekly instillations was followed by a maintenance phase consisting of 1 instillation given every 3 months. A second 6-week course of BCG was administered to initial failure followed again by a quarterly maintenance therapy. The response rate for patients treated with one 6-week course was 56%, while complete response was achieved in 72% when both treatment courses were considered. Follow-up period lasted at least 2 years after each course of BCG. These results suggest that additional courses of BCG increase the prophylactic efficacy of intracavitary BCG. Regarding the purified protein derivative (PPD) skin test and granulomatous response in the bladder, it has been shown in the present study that, although favourable results occurred more frequently among patients with either PPD conversion from negative to positive or vesical granuloma formation, neither of these indices should be considered reliable prognostic indicators.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076932     DOI: 10.1007/BF02549774

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  19 in total

1.  Re: Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.

Authors:  H W Herr
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

2.  Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.

Authors:  D R Kelley; T L Ratliff; W J Catalona; A Shapiro; J M Lage; W C Bauer; E O Haaff; S M Dresner
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

3.  Bacillus Calmette-Guerin immunotherapy for bladder cancer.

Authors:  D L Lamm
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

4.  Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.

Authors:  E O Haaff; S M Dresner; T L Ratliff; W J Catalona
Journal:  J Urol       Date:  1986-10       Impact factor: 7.450

5.  A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.

Authors:  R A Badalament; H W Herr; G Y Wong; C Gnecco; C M Pinsky; W F Whitmore; W R Fair; H F Oettgen
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

6.  Bacillus Calmette-Guerin for superficial transitional cell carcinoma of the bladder.

Authors:  P F Schellhammer; L E Ladaga; M B Fillion
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

7.  Prognostic value of purified protein derivative skin test and granuloma formation in patients treated with intravesical bacillus Calmette-Guerin.

Authors:  D R Kelley; E O Haaff; M Becich; J Lage; W C Bauer; S M Dresner; W J Catalona; T L Ratliff
Journal:  J Urol       Date:  1986-02       Impact factor: 7.450

8.  Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial.

Authors:  M A Hudson; T L Ratliff; D P Gillen; E O Haaff; S M Dresner; W J Catalona
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

9.  Intravesical administration of bacillus Calmette-Guérin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial.

Authors:  C M Pinsky; F J Camacho; D Kerr; N L Geller; F A Klein; H A Herr; W F Whitmore; H F Oettgen
Journal:  Cancer Treat Rep       Date:  1985-01

10.  Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.

Authors:  D L Lamm; D E Thor; S C Harris; J A Reyna; V D Stogdill; H M Radwin
Journal:  J Urol       Date:  1980-07       Impact factor: 7.450

View more
  2 in total

1.  BCG vaccine in urinary bladder cancer.

Authors:  S A Brosman
Journal:  West J Med       Date:  1991-12

2.  BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes.

Authors:  M D Melekos; I Zarakovitis; K Dandinis; E Fokaefs; H Chionis; H Dauaher; G Barbalias
Journal:  Int Urol Nephrol       Date:  1996       Impact factor: 2.370

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.